Director Jonathan Hirt Hagen filed a Form 4 with the SEC on November 2, 2026, disclosing a transaction in Erie Indemnity Company (NASDAQ:ERIE) Class A Common Stock derivative securities dated October 31, 2026.
A Form 144 notice of proposed sale was filed on November 2, 2026, by Sumit Singh, identified as an officer and director of Chewy, Inc., disclosing a planned sale of 3,228 Class A shares through an account held by his spouse, Aseemita Malholtra.
Chewy, Inc. officer and director Sumit Singh filed a Form 144 notice of proposed sale on November 2, 2026, covering 23,002 Class A shares with an aggregate market value of $492,242.80.
Director and 10% owner Elizabeth A. Vorsheck filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 65 Directors' Deferred Compensation Share Credits in Erie Indemnity Company Class A Common Stock on October 31, 2026.
Melinda J. Truex, a director of Lakeland Financial Corp, filed a Form 144 notice on November 2, 2026, indicating a proposed sale of 22,500 common shares with an aggregate market value of $1,369,577.75 through NewEdge Securities, LLC on the NASDAQ exchange.
CarGurus, Inc. officer Ismail El Shareef filed a Form 144 notice of proposed sale of 1,964 Class A shares, dated November 2, 2026, through Fidelity Brokerage Services LLC on the NASDAQ exchange.
Director Melinda Jo Truex filed a Form 4 on November 2, 2026, disclosing the sale of 22,500 shares of Lakeland Financial Corporation common stock on October 29, 2026, through an LLC in which she holds an indirect beneficial interest.
Director William H. Hughes III filed a Form 4 with the SEC on November 2, 2026, disclosing the open-market purchase of 200 shares of Beacon Financial Corp common stock on October 29, 2026.
U S Global Investors Inc CFO Lisa Callicotte filed a Form 4 on November 2, 2026, reporting the acquisition of 363 shares of Class A Common Stock on October 30, 2026, under the company's employee stock purchase plan.
Boston Scientific Corporation (NYSE:BSX) issued a press release on November 2, 2026, announcing positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX Pro Left Atrial Appendage Closure Device.